Archives

  • 2026-11
  • 2026-10
  • 2026-09
  • 2026-08
  • 2026-07
  • 2026-06
  • 2026-05
  • 2026-04
  • 2026-03
  • 2026-02
  • 2026-01
  • 2025-12
  • 2025-11
  • 2025-10
  • 2025-09
  • 2025-08
  • 2025-07
  • 2025-06
  • Thymosin-β 4 Drives Angiogenesis in Limb Ischemia via Notch/

    2026-07-21

    Thymosin-β 4 Drives Angiogenesis in Limb Ischemia via Notch/NF-κB Pathways

    Study Background and Research Question

    Critical limb ischemia (CLI) is a severe manifestation of peripheral arterial disease characterized by progressive arterial narrowing and a high risk of limb loss. Conventional therapies, such as surgical or interventional revascularization, are not viable for many patients, rendering amputation the only option in advanced cases. Given these limitations, the scientific community has prioritized the development of molecular strategies to induce therapeutic neovascularization and restore tissue perfusion. Thymosin-β 4 (Tβ4), a ubiquitous G-actin-sequestering peptide, has previously been implicated in endothelial cell migration, inflammation regulation, and wound healing. However, its precise mechanisms and efficacy in promoting angiogenesis within the context of CLI remained unclear. The study by Lv et al. (DOI:10.3892/ijmm.2020.4701) sought to elucidate whether Tβ4 can drive angiogenesis in CLI and to define the signaling pathways underlying its action.

    Key Innovation from the Reference Study

    The central innovation of this research lies in its mechanistic dissection of Tβ4's pro-angiogenic effects in CLI, specifically through the coordinated regulation of the Notch and NF-κB pathways. By employing both in vitro and in vivo models, the authors provide compelling evidence that Tβ4 overexpression enhances endothelial cell viability, migration, and angiogenic potential. Importantly, the study demonstrates that pharmacological inhibition of Notch (using DAPT) and NF-κB (using BMS-345541, a selective IKK-1/IKK-2 inhibitor) blocks these effects, and that Tβ4 can partially reverse the inhibitory impact of these pathway antagonists. This establishes a causal link between Tβ4-induced angiogenesis and the activation of Notch/NF-κB signaling.

    Methods and Experimental Design Insights

    To investigate the mechanistic role of Tβ4 in angiogenesis, the authors utilized a lentiviral vector to overexpress Tβ4 in both human umbilical vein endothelial cells (HUVECs) and a mouse model of CLI. The study incorporated established assays to quantify cellular phenotypes:

    • MTT assay for cell viability
    • Tube formation assay for in vitro angiogenesis
    • Wound healing assay for migratory capacity

    To interrogate the pathway dependencies, the Notch inhibitor DAPT and the NF-κB pathway inhibitor BMS-345541 were applied to both HUVECs and CLI mice. Downstream molecular markers were assessed using Western blotting, qPCR, immunofluorescence, and immunohistochemistry, focusing on the expression of angiogenesis-related factors (Ang2, tie2, VEGFA, CD31, α-SMA) and key pathway mediators (NOTCH1 intracellular domain [N1ICD], Notch3, NF-κB, phosphorylated p65).

    Core Findings and Why They Matter

    Lv et al. provide several lines of evidence supporting the pro-angiogenic action of Tβ4 in the CLI context (reference study):

    • Enhanced Endothelial Viability and Angiogenesis: Tβ4 overexpression increased HUVEC viability, tube formation, and migration, key hallmarks of angiogenic potential.
    • Upregulation of Angiogenic and Pathway Markers: Expression of Ang2, tie2, VEGFA, N1ICD, Notch3, NF-κB, and phosphorylated p65 were elevated in Tβ4-treated cells and CLI mouse muscle tissue.
    • Antagonistic Effects of Pathway Inhibitors: Both DAPT and BMS-345541 suppressed Tβ4-induced angiogenic phenotypes and marker expression. Notably, Tβ4 could partially counteract the inhibitory effects of these compounds, implicating Notch and NF-κB as critical nodes for Tβ4 function in angiogenesis.

    These results illuminate the interplay between Notch and NF-κB signaling in vascular remodeling and suggest that targeted modulation of these pathways can influence therapeutic neovascularization. In the context of inflammation research and apoptosis induction in cancer cells, the findings also reinforce the importance of the NF-κB pathway as a convergent mechanism linking angiogenesis, immune modulation, and cell survival.

    Comparison with Existing Internal Articles

    Previous internal reviews on BMS-345541, such as "BMS-345541: Precision IKK-1/IKK-2 Inhibitor for Inflammation Research" and "BMS-345541: Precision IKK-1/IKK-2 Inhibition in Angiogenesis Research", have highlighted the compound's selectivity for IKK-1/IKK-2 and its utility in dissecting NF-κB pathway contributions in diverse disease models. The present study builds on these insights by directly applying BMS-345541 in a vascular regeneration setting, providing experimental confirmation that NF-κB inhibition can blunt angiogenesis driven by upstream pro-angiogenic signals. This complements prior workflow recommendations for using BMS-345541 to interrogate cytokine production suppression, inflammation, and apoptosis mechanisms. Moreover, it demonstrates the translational relevance of IKK-1/IKK-2 inhibitors not only in inflammation and cancer research but also in vascular remodeling and tissue repair contexts.

    Limitations and Transferability

    While this study offers robust genetic and pharmacological evidence for Tβ4's role in CLI-induced angiogenesis, several limitations warrant consideration. The primary models—HUVECs for in vitro assays and mouse CLI for in vivo studies—may not fully recapitulate the cellular complexity of human peripheral artery disease. The effects of Tβ4 and pathway inhibition in other vascular beds or disease states remain to be defined. Additionally, while BMS-345541 demonstrates pathway-specific inhibition, its pharmacokinetics and off-target effects in chronic CLI models have not been fully characterized. Consequently, translating these findings into clinical protocols requires further validation in larger animal models and, ultimately, in patient cohorts.

    Protocol Parameters

    • BMS-345541 inhibition: In cell-based studies, pretreatment with BMS-345541 at concentrations ranging from 1 to 100 μM, with typical incubation times of around 1 hour, was used to block NF-κB pathway activation and assess effects on angiogenic phenotypes (reference study).
    • In vivo administration: For mouse models, dose-dependent inhibition of LPS-induced cytokine production by BMS-345541 has been reported at 3–100 mg/kg, administered intravenously or orally, according to the product information. Adjustments may be necessary depending on disease model and experimental endpoints.
    • Pathway interplay: When modeling Tβ4 effects, ensure sequential or co-administration of pathway inhibitors to accurately assess mechanistic dependencies involving Notch and NF-κB signaling.

    Research Support Resources

    To replicate or expand on these findings, researchers can employ BMS-345541 (free base) (SKU B4655), a well-characterized IKK-1/IKK-2 inhibitor available from APExBIO, to selectively modulate the NF-κB pathway in angiogenesis, inflammation, and cancer research workflows. Detailed storage, solubility, and dosing parameters are provided in the product dossier to support robust and reproducible experimental design.